{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:28:32Z","timestamp":1791919712229,"version":"4.3.4"},"reference-count":124,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCHTS"],"published-print":{"date-parts":[[2021,1,13]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The emergence of drug-resistant strains among the variety of pathogens worsens the\nsituation in today\u2019s scenario. In such a situation, a very heavy demand for developing the new\nantibiotics has arisen, but unfortunately, very limited success has been achieved in this arena till\nnow. Infectious diseases usually make their impression in the form of severe pathology.\nIntracellular pathogens use the host\u2019s cell machinery for their survival. They alter the gene\nexpression of several host\u2019s pathways and endorse to shut down the cell\u2019s innate defense pathway\nlike apoptosis and autophagy. Intracellular pathogens are co-evolved with hosts and have a striking\nability to manipulate the host\u2019s factors. They also mimic the host molecules and secrete them to\nprevent the host\u2019s proper immune response against them for their survival. Intracellular pathogens\nin chronic diseases create excessive inflammation. This excessive inflammation manifests in\npathology. Host directed therapy could be alternative medicine in this situation; it targets the host\nfactors, and abrogates the replication and persistence of pathogens inside the cell. It also provokes\nthe anti-microbial immune response against the pathogen and reduces the exacerbation by\nenhancing the healing process to the site of pathology. HDT targets the host\u2019s factor involved in a\ncertain pathway that ultimately targets the pathogen life cycle and helps in eradication of the\npathogen. In such a scenario, HDT could also play a significant role in the treatment of drugsensitive\nas well with drug resistance strains because it targets the host\u2019s factors, which favors the\npathogen survival inside the cell.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1386207323999200728115857","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T02:37:47Z","timestamp":1595990267000},"page":"59-70","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Host-directed Therapy: A New Arsenal to Come"],"prefix":"10.2174","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5164-9921","authenticated-orcid":true,"given":"Mradul","family":"Mohan","sequence":"first","affiliation":[{"name":"National Institute of Malaria Research, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debapriya","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Center for Biotechnology, School of Pharmaceutical Sciences, SOA Deemed University, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/jac\/dkn241","volume":"62","author":"Hawkey P.M.","year":"2008","unstructured":"Hawkey P.M.; The growing burden of antimicrobial resistance. J Antimicrob Chemother 2008,62(Suppl. 1),i1-i9","journal-title":"J Antimicrob Chemother"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nrmicro727","volume":"1","author":"Walsh C.","year":"2003","unstructured":"Walsh C.; Where will new antibiotics come from? Nat Rev Microbiol 2003,1(1),65-70","journal-title":"Nat Rev Microbiol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"Tacconelli E.","year":"2018","unstructured":"Tacconelli E.; Carrara E.; Savoldi A.; Harbarth S.; Mendelson M.; Monnet D.L.; Pulcini C.; Kahlmeter G.; Kluytmans J.; Carmeli Y.; Ouellette M.; Outterson K.; Patel J.; Cavaleri M.; Cox E.M.; Houchens C.R.; Grayson M.L.; Hansen P.; Singh N.; Theuretzbacher U.; Magrini N.; Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis WHO Pathogens Priority List Working Group2018,18(3),318-327","journal-title":"Lancet Infect Dis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1128\/MMBR.00016-10","volume":"74","author":"Davies J.","year":"2010","unstructured":"Davies J.; Davies D.; Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 2010,74(3),417-433","journal-title":"Microbiol Mol Biol Rev"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/MCP.0000000000000271","volume":"22","author":"Maeurer M.","year":"2016","unstructured":"Maeurer M.; Rao M.; Zumla A.; Host-directed therapies for antimicrobial resistant respiratory tract infections. Curr Opin Pulm Med 2016,22(3),203-211","journal-title":"Curr Opin Pulm Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/34571","volume":"391","author":"Berger E.A.","year":"1998","unstructured":"Berger E.A.; Doms R.W.; Feny\u00f6 E.M.; Korber B.T.; Littman D.R.; Moore J.P.; Sattentau Q.J.; Schuitemaker H.; Sodroski J.; Weiss R.A.; A new classification for HIV-1. Nature 1998,391(6664),240","journal-title":"Nature"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S0092-8674(00)81429-4","volume":"93","author":"Littman D.R.","year":"1998","unstructured":"Littman D.R.; Chemokine receptors: Keys to AIDS pathogenesis? Cell 1998,93(5),677-680","journal-title":"Cell"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1126\/science.272.5270.1955","volume":"272","author":"Alkhatib G.","year":"1996","unstructured":"Alkhatib G.; Combadiere C.; Broder C.C.; Feng Y.; Kennedy P.E.; Murphy P.M.; Berger E.A.; CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996,272(5270),1955-1958","journal-title":"Science"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/381661a0","volume":"381","author":"Deng H.","year":"1996","unstructured":"Deng H.; Liu R.; Ellmeier W.; Choe S.; Unutmaz D.; Burkhart M.; Di Marzio P.; Marmon S.; Sutton R.E.; Hill C.M.; Davis C.B.; Peiper S.C.; Schall T.J.; Littman D.R.; Landau N.R.; Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996,381(6584),661-666","journal-title":"Nature"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0092-8674(00)81314-8","volume":"85","author":"Doranz B.J.","year":"1996","unstructured":"Doranz B.J.; Rucker J.; Yi Y.; Smyth R.J.; Samson M.; Peiper S.C.; Parmentier M.; Collman R.G.; Doms R.W.; A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996,85(7),1149-1158","journal-title":"Cell"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1073\/pnas.97.7.3388","volume":"97","author":"Vila-Coro A.J.","year":"2000","unstructured":"Vila-Coro A.J.; Mellado M.; Mart\u00edn de Ana A.; Lucas P.; del Real G.; Mart\u00ednez-A C.; Rodr\u00edguez-Frade J.M.; HIV-1 infection through the CCR5 receptor is blocked by receptor dimerization. Proc Natl Acad Sci USA 2000,97(7),3388-3393","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1086\/589289","volume":"47","author":"MacArthur R.D.","year":"2008","unstructured":"MacArthur R.D.; Novak R.M.; Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 2008,47(2),236-241","journal-title":"Clin Infect Dis"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/med.20138","volume":"29","author":"Qian K.","year":"2009","unstructured":"Qian K.; Morris-Natschke S.L.; Lee K.H.; HIV entry inhibitors and their potential in HIV therapy. Med Res Rev 2009,29(2),369-393","journal-title":"Med Res Rev"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","volume":"568","author":"Gupta R.K.","year":"2019","unstructured":"Gupta R.K.; Abdul-Jawad S.; McCoy L.E.; Mok H.P.; Peppa D.; Salgado M.; Martinez-Picado J.; Nijhuis M.; Wensing A.M.J.; Lee H.; Grant P.; Nastouli E.; Lambert J.; Pace M.; Salasc F.; Monit C.; Innes A.J.; Muir L.; Waters L.; Frater J.; Lever A.M.L.; Edwards S.G.; Gabriel I.H.; Olavarria E.; HIV-1 remission following CCR5\u039432\/\u039432 haematopoietic stem-cell transplantation. Nature 2019,568(7751),244-248","journal-title":"Nature"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1128\/AAC.50.4.1470-1479.2006","volume":"50","author":"Malakhov M.P.","year":"2006","unstructured":"Malakhov M.P.; Aschenbrenner L.M.; Smee D.F.; Wandersee M.K.; Sidwell R.W.; Gubareva L.V.; Mishin V.P.; Hayden F.G.; Kim D.H.; Ing A.; Campbell E.R.; Yu M.; Fang F.; Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006,50(4),1470-1479","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1086\/522609","volume":"196","author":"Belser J.A.","year":"2007","unstructured":"Belser J.A.; Lu X.; Szretter K.J.; Jin X.; Aschenbrenner L.M.; Lee A.; Hawley S.; Kim D.H.; Malakhov M.P.; Yu M.; Fang F.; Katz J.M.; DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 2007,196(10),1493-1499","journal-title":"J Infect Dis"},{"key":"ref=17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007838","volume":"4","author":"Triana-Baltzer G.B.","year":"2009","unstructured":"Triana-Baltzer G.B.; Gubareva L.V.; Klimov A.I.; Wurtman D.F.; Moss R.B.; Hedlund M.; Larson J.L.; Belshe R.B.; Fang F.; Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One 2009,4(11)","journal-title":"PLoS One"},{"key":"ref=18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007788","volume":"4","author":"Triana-Baltzer G.B.","year":"2009","unstructured":"Triana-Baltzer G.B.; Gubareva L.V.; Nicholls J.M.; Pearce M.B.; Mishin V.P.; Belser J.A.; Chen L.M.; Chan R.W.; Chan M.C.; Hedlund M.; Larson J.L.; Moss R.B.; Katz J.M.; Tumpey T.M.; Fang F.; Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS One 2009,4(11)","journal-title":"PLoS One"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1093\/infdis\/jis622","volume":"206","author":"Moss R.B.","year":"2012","unstructured":"Moss R.B.; Hansen C.; Sanders R.L.; Hawley S.; Li T.; Steigbigel R.T.; A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis 2012,206(12),1844-1851","journal-title":"J Infect Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.celrep.2016.12.045","volume":"18","author":"Meertens L.","year":"2017","unstructured":"Meertens L.; Labeau A.; Dejarnac O.; Cipriani S.; Sinigaglia L.; Bonnet-Madin L.; Le Charpentier T.; Hafirassou M.L.; Zamborlini A.; Cao-Lormeau V.M.; Coulpier M.; Miss\u00e9 D.; Jouvenet N.; Tabibiazar R.; Gressens P.; Schwartz O.; Amara A.; Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses. Cell Rep 2017,18(2),324-333","journal-title":"Cell Rep"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","volume":"146","author":"Ni Y.","year":"2014","unstructured":"Ni Y.; Lempp F.A.; Mehrle S.; Nkongolo S.; Kaufman C.; F\u00e4lth M.; Stindt J.; K\u00f6niger C.; Nassal M.; Kubitz R.; S\u00fcltmann H.; Urban S.; Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 2014,146(4),1070-1083","journal-title":"Gastroenterology"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/nrgastro.2016.126","volume":"13","author":"Lempp F.A.","year":"2016","unstructured":"Lempp F.A.; Ni Y.; Urban S.; Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options. Nat Rev Gastroenterol Hepatol 2016,13(10),580-589","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jhep.2016.04.013","volume":"65","author":"Blank A.","year":"2016","unstructured":"Blank A.; Markert C.; Hohmann N.; Carls A.; Mikus G.; Lehr T.; Alexandrov A.; Haag M.; Schwab M.; Urban S.; Haefeli W.E.; First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol 2016,65(3),483-489","journal-title":"J Hepatol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd.2017.162","volume":"17","author":"Kaufmann S.H.E.","year":"2018","unstructured":"Kaufmann S.H.E.; Dorhoi A.; Hotchkiss R.S.; Bartenschlager R.; Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov 2018,17(1),35-56","journal-title":"Nat Rev Drug Discov"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature10348","volume":"477","author":"Carette J.E.","year":"2011","unstructured":"Carette J.E.; Raaben M.; Wong A.C.; Herbert A.S.; Obernosterer G.; Mulherkar N.; Kuehne A.I.; Kranzusch P.J.; Griffin A.M.; Ruthel G.; Dal Cin P.; Dye J.M.; Whelan S.P.; Chandran K.; Brummelkamp T.R.; Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 2011,477(7364),340-343","journal-title":"Nature"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1126\/science.1252480","volume":"344","author":"Jae L.T.","year":"2014","unstructured":"Jae L.T.; Raaben M.; Herbert A.S.; Kuehne A.I.; Wirchnianski A.S.; Soh T.K.; Stubbs S.H.; Janssen H.; Damme M.; Saftig P.; Whelan S.P.; Dye J.M.; Brummelkamp T.R.; Virus entry. Lassa virus entry requires a trigger-induced receptor switch. Science 2014,344(6191),1506-1510","journal-title":"Science"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1128\/mBio.01818-17","volume":"9","author":"Hulseberg C.E.","year":"2018","unstructured":"Hulseberg C.E.; F\u00e9n\u00e9ant L.; Szyma\u0144ska K.M.; White J.M.; Lamp1 increases the efficiency of lassa virus infection by promoting fusion in less acidic endosomal compartments. MBio 2018,9(1),9","journal-title":"MBio"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1128\/JVI.02185-18","volume":"93","author":"Hulseberg C.E.","year":"2019","unstructured":"Hulseberg C.E.; F\u00e9n\u00e9ant L.; Szyma\u0144ska-de Wijs K.M.; Kessler N.P.; Nelson E.A.; Shoemaker C.J.; Schmaljohn C.S.; Polyak S.J.; White J.M.; Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses. J Virol 2019,93(8),93","journal-title":"J Virol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"Zhu N.","year":"2020","unstructured":"Zhu N.; Zhang D.; Wang W.; Li X.; Yang B.; Song J.; Zhao X.; Huang B.; Shi W.; Lu R.; Niu P.; Zhan F.; Ma X.; Wang D.; Xu W.; Wu G.; Gao G.F.; Tan W.; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020,382(8),727-733","journal-title":"N Engl J Med"},{"key":"ref=30","first-page":"271","volume":"181","author":"Hoffmann M","year":"2020","unstructured":"Hoffmann M; Kleine-Weber H; Schroeder S; Kruger N; Herrler T; Erichsen S; SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease. Inhibitor Cell 2020,181,271-280","journal-title":"Inhibitor Cell"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"Zhou P.","year":"2020","unstructured":"Zhou P.; Yang X.L.; Wang X.G.; Hu B.; Zhang L.; Zhang W.; Si H.R.; Zhu Y.; Li B.; Huang C.L.; Chen H.D.; Chen J.; Luo Y.; Guo H.; Jiang R.D.; Liu M.Q.; Chen Y.; Shen X.R.; Wang X.; Zheng X.S.; Zhao K.; Chen Q.J.; Deng F.; Liu L.L.; Yan B.; Zhan F.X.; Wang Y.Y.; Xiao G.F.; Shi Z.L.; A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020,579(7798),270-273","journal-title":"Nature"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.1128\/JVI.00094-12","volume":"86","author":"Kawase M.","year":"2012","unstructured":"Kawase M.; Shirato K.; van der Hoek L.; Taguchi F.; Matsuyama S.; Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol 2012,86(12),6537-6545","journal-title":"J Virol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.antiviral.2015.01.011","volume":"116","author":"Zhou Y.","year":"2015","unstructured":"Zhou Y.; Vedantham P.; Lu K.; Agudelo J.; Carrion R.; Nunneley J.W.; Barnard D.; P\u00f6hlmann S.; McKerrow J.H.; Renslo A.R.; Simmons G.; Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res 2015,116,76-84","journal-title":"Antiviral Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"31448","DOI":"10.1074\/jbc.M112398200","volume":"277","author":"Ambrosino C.","year":"2002","unstructured":"Ambrosino C.; Palmieri C.; Puca A.; Trimboli F.; Schiavone M.; Olimpico F.; Ruocco M.R.; di Leva F.; Toriello M.; Quinto I.; Venuta S.; Scala G.; Physical and functional interaction of HIV-1 Tat with E2F-4, a transcriptional regulator of mammalian cell cycle. J Biol Chem 2002,277(35),31448-31458","journal-title":"J Biol Chem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1128\/JVI.74.2.652-660.2000","volume":"74","author":"Kashanchi F.","year":"2000","unstructured":"Kashanchi F.; Agbottah E.T.; Pise-Masison C.A.; Mahieux R.; Duvall J.; Kumar A.; Brady J.N.; Cell cycle-regulated transcription by the human immunodeficiency virus type 1 Tat transactivator. J Virol 2000,74(2),652-660","journal-title":"J Virol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"8130","DOI":"10.1074\/jbc.273.14.8130","volume":"273","author":"Kundu M.","year":"1998","unstructured":"Kundu M.; Sharma S.; De Luca A.; Giordano A.; Rappaport J.; Khalili K.; Amini S.; HIV-1 Tat elongates the G1 phase and indirectly promotes HIV-1 gene expression in cells of glial origin. J Biol Chem 1998,273(14),8130-8136","journal-title":"J Biol Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1742-4690-2-20","volume":"2","author":"Liang W.S.","year":"2005","unstructured":"Liang W.S.; Maddukuri A.; Teslovich T.M.; de la Fuente C.; Agbottah E.; Dadgar S.; Kehn K.; Hautaniemi S.; Pumfery A.; Stephan D.A.; Kashanchi F.; Therapeutic targets for HIV-1 infection in the host proteome. Retrovirology 2005,2,20","journal-title":"Retrovirology"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1074-7613(00)80065-5","volume":"10","author":"Cohen G.B.","year":"1999","unstructured":"Cohen G.B.; Gandhi R.T.; Davis D.M.; Mandelboim O.; Chen B.K.; Strominger J.L.; Baltimore D.; The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999,10(6),661-671","journal-title":"Immunity"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/00002030-200202150-00005","volume":"16","author":"Lozano J.M.","year":"2002","unstructured":"Lozano J.M.; Gonz\u00e1lez R.; Kindel\u00e1n J.M.; Rouas-Freiss N.; Caballos R.; Dausset J.; Carosella E.D.; Pe\u00f1a J.; Monocytes and T lymphocytes in HIV-1-positive patients express HLA-G molecule. AIDS 2002,16(3),347-351","journal-title":"AIDS"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3389\/fimmu.2017.01120","volume":"8","author":"Bhattacharya D.","year":"2017","unstructured":"Bhattacharya D.; Danaviah S.; Muema D.M.; Akilimali N.A.; Moodley P.; Ndung\u2019u T.; Das G.; Cellular Architecture of Spinal Granulomas and the Immunological Response in Tuberculosis Patients Coinfected with HIV. Front Immunol 2017,8,1120","journal-title":"Front Immunol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"734","DOI":"10.3389\/fimmu.2018.00734","volume":"9","author":"Kleinman A.J.","year":"2018","unstructured":"Kleinman A.J.; Sivanandham R.; Pandrea I.; Chougnet C.A.; Apetrei C.; Regulatory T.; Regulatory T.; Cells As Potential Targets for HIV Cure Research. Front Immunol 2018,9,734","journal-title":"Front Immunol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1053\/j.gastro.2005.06.031","volume":"129","author":"Nakagawa M.","year":"2005","unstructured":"Nakagawa M.; Sakamoto N.; Tanabe Y.; Koyama T.; Itsui Y.; Takeda Y.; Chen C.H.; Kakinuma S.; Oooka S.; Maekawa S.; Enomoto N.; Watanabe M.; Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology 2005,129(3),1031-1041","journal-title":"Gastroenterology"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/hep.22835","volume":"49","author":"Flisiak R.","year":"2009","unstructured":"Flisiak R.; Feinman S.V.; Jablkowski M.; Horban A.; Kryczka W.; Pawlowska M.; Heathcote J.E.; Mazzella G.; Vandelli C.; Nicolas-M\u00e9tral V.; Grosgurin P.; Liz J.S.; Scalfaro P.; Porchet H.; Crabb\u00e9 R.; The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-na\u00efve hepatitis C patients. Hepatology 2009,49(5),1460-1468","journal-title":"Hepatology"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jhep.2012.02.024","volume":"57","author":"Hopkins S.","year":"2012","unstructured":"Hopkins S.; DiMassimo B.; Rusnak P.; Heuman D.; Lalezari J.; Sluder A.; Scorneaux B.; Mosier S.; Kowalczyk P.; Ribeill Y.; Baugh J.; Gallay P.; The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J Hepatol 2012,57(1),47-54","journal-title":"J Hepatol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.antiviral.2016.12.022","volume":"139","author":"Kuivanen S.","year":"2017","unstructured":"Kuivanen S.; Bespalov M.M.; Nandania J.; Ianevski A.; Velagapudi V.; De Brabander J.K.; Kainov D.E.; Vapalahti O.; Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika virus infection in vitro and differentially affect cellular signaling, transcription and metabolism. Antiviral Res 2017,139,117-128","journal-title":"Antiviral Res"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.chom.2017.01.004","volume":"21","author":"Miner J.J.","year":"2017","unstructured":"Miner J.J.; Diamond M.S.; Zika Virus Pathogenesis and Tissue Tropism. Cell Host Microbe 2017,21(2),134-142","journal-title":"Cell Host Microbe"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","volume":"110","author":"Rossignol J.F.","year":"2014","unstructured":"Rossignol J.F.; Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res 2014,110,94-103","journal-title":"Antiviral Res"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1473-3099(14)70717-0","volume":"14","author":"Haffizulla J.","year":"2014","unstructured":"Haffizulla J.; Hartman A.; Hoppers M.; Resnick H.; Samudrala S.; Ginocchio C.; Bardin M.; Rossignol J.F.; Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b\/3 trial. Lancet Infect Dis US Nitazoxanide Influenza Clinical Study Group2014,14(7),609-618","journal-title":"Lancet Infect Dis"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.virol.2009.06.032","volume":"392","author":"Spiropoulou C.F.","year":"2009","unstructured":"Spiropoulou C.F.; Ranjan P.; Pearce M.B.; Sealy T.K.; Albari\u00f1o C.G.; Gangappa S.; Fujita T.; Rollin P.E.; Nichol S.T.; Ksiazek T.G.; Sambhara S.; RIG-I activation inhibits ebolavirus replication. Virology 2009,392(1),11-15","journal-title":"Virology"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"10968","DOI":"10.1073\/pnas.1901214116","volume":"116","author":"Ashraf U.","year":"2019","unstructured":"Ashraf U.; Tengo L.; Le Corre L.; Fournier G.; Busca P.; McCarthy A.A.; Rameix-Welti M.A.; Gravier-Pelletier C.; Ruigrok R.W.H.; Jacob Y.; Vidalain P.O.; Pietrancosta N.; Cr\u00e9pin T.; Naffakh N.; Destabilization of the human RED-SMU1 splicing complex as a basis for host-directed antiinfluenza strategy. Proc Natl Acad Sci USA 2019,116(22),10968-10977","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/v10090453","volume":"10","author":"Saiz J.C.","year":"2018","unstructured":"Saiz J.C.; Oya N.J.; Bl\u00e1zquez A.B.; Escribano-Romero E.; Mart\u00edn-Acebes M.A.; Host-Directed Antivirals: A Realistic Alternative to Fight Zika Virus. Viruses 2018,10(9),10","journal-title":"Viruses"},{"key":"ref=52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105938","volume":"55","author":"Devaux C.A.","year":"2020","unstructured":"Devaux C.A.; Rolain J.M.; Colson P.; Raoult D.; New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020,55(5)","journal-title":"Int J Antimicrob Agents"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41565-020-0674-9","volume":"15","author":"Hu T.Y.","year":"2020","unstructured":"Hu T.Y.; Frieman M.; Wolfram J.; Insights from nanomedicine into chloroquine efficacy against COVID-19. Nat Nanotechnol 2020,15(4),247-249","journal-title":"Nat Nanotechnol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nri3463","volume":"13","author":"Heim M.H.","year":"2013","unstructured":"Heim M.H.; 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol 2013,13(7),535-542","journal-title":"Nat Rev Immunol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/ni.3212","volume":"16","author":"Wack A.","year":"2015","unstructured":"Wack A.; Terczy\u0144ska-Dyla E.; Hartmann R.; Guarding the frontiers: the biology of type III interferons. Nat Immunol 2015,16(8),802-809","journal-title":"Nat Immunol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.jhep.2014.07.022","volume":"61","author":"Muir A.J.","year":"2014","unstructured":"Muir A.J.; Arora S.; Everson G.; Flisiak R.; George J.; Ghalib R.; Gordon S.C.; Gray T.; Greenbloom S.; Hassanein T.; Hillson J.; Horga M.A.; Jacobson I.M.; Jeffers L.; Kowdley K.V.; Lawitz E.; Lueth S.; Rodriguez-Torres M.; Rustgi V.; Shemanski L.; Shiffman M.L.; Srinivasan S.; Vargas H.E.; Vierling J.M.; Xu D.; Lopez-Talavera J.C.; Zeuzem S.; A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol EMERGE study group2014,61(6),1238-1246","journal-title":"J Hepatol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"Terrault N.A.","year":"2016","unstructured":"Terrault N.A.; Bzowej N.H.; Chang K.M.; Hwang J.P.; Jonas M.M.; Murad M.H.; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016,63(1),261-283","journal-title":"Hepatology"},{"key":"ref=58","unstructured":"Guidelines approved by the guidelines review committee. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3389\/fimmu.2018.00597","volume":"9","author":"Khandia R.","year":"2018","unstructured":"Khandia R.; Munjal A.; Dhama K.; Karthik K.; Tiwari R.; Malik Y.S.; Singh R.K.; Chaicumpa W.; Modulation of Dengue\/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection. Front Immunol 2018,9,597","journal-title":"Front Immunol"},{"key":"ref=60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102452","author":"Liu B.","year":"2020","unstructured":"Liu B.; Li M.; Zhou Z.; Guan X.; Xiang Y.; Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun 2020","journal-title":"J Autoimmun"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.abb8925","volume":"368","author":"Moore J.B.","year":"2020","unstructured":"Moore J.B.; June C.H.; Cytokine release syndrome in severe COVID-19. Science 2020,368(6490),473-474","journal-title":"Science"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.1038\/ncomms7049","volume":"6","author":"Bhalla K.","year":"2015","unstructured":"Bhalla K.; Chugh M.; Mehrotra S.; Rathore S.; Tousif S.; Prakash Dwivedi V.; Prakash P.; Kumar Samuchiwal S.; Kumar S.; Kumar Singh D.; Ghanwat S.; Kumar D.; Das G.; Mohmmed A.; Malhotra P.; Ranganathan A.; Host ICAMs play a role in cell invasion by Mycobacterium tuberculosis and Plasmodium falciparum. Nat Commun 2015,6,6049","journal-title":"Nat Commun"},{"key":"ref=63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2018.12.008","author":"Dwivedi V.P.","year":"2019","unstructured":"Dwivedi V.P.; Bhattacharya D.; Singh M.; Bhaskar A.; Kumar S.; Fatima S.; Sobia P.; Kaer L.V.; Das G.; Allicin enhances antimicrobial activity of macrophages during Mycobacterium tuberculosis infection. J Ethnopharmacol 2019","journal-title":"J Ethnopharmacol"},{"key":"ref=64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004770","volume":"11","author":"Napier R.J.","year":"2015","unstructured":"Napier R.J.; Norris B.A.; Swimm A.; Giver C.R.; Harris W.A.; Laval J.; Napier B.A.; Patel G.; Crump R.; Peng Z.; Bornmann W.; Pulendran B.; Buller R.M.; Weiss D.S.; Tirouvanziam R.; Waller E.K.; Kalman D.; Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity. PLoS Pathog 2015,11(3)","journal-title":"PLoS Pathog"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.chom.2011.09.010","volume":"10","author":"Napier R.J.","year":"2011","unstructured":"Napier R.J.; Rafi W.; Cheruvu M.; Powell K.R.; Zaunbrecher M.A.; Bornmann W.; Salgame P.; Shinnick T.M.; Kalman D.; Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe 2011,10(5),475-485","journal-title":"Cell Host Microbe"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"910","DOI":"10.4049\/jimmunol.167.2.910","volume":"167","author":"Noss E.H.","year":"2001","unstructured":"Noss E.H.; Pai R.K.; Sellati T.J.; Radolf J.D.; Belisle J.; Golenbock D.T.; Boom W.H.; Harding C.V.; Toll-like receptor 2-dependent inhibition of macrophage class II MHC expression and antigen processing by 19-kDa lipoprotein of Mycobacterium tuberculosis. J Immunol 2001,167(2),910-918","journal-title":"J Immunol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1146\/annurev.cellbio.22.010305.104619","volume":"22","author":"Martens S.","year":"2006","unstructured":"Martens S.; Howard J.; The interferon-inducible GTPases. Annu Rev Cell Dev Biol 2006,22,559-589","journal-title":"Annu Rev Cell Dev Biol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1128\/MMBR.00032-13","volume":"77","author":"Hawn T.R.","year":"2013","unstructured":"Hawn T.R.; Matheson A.I.; Maley S.N.; Vandal O.; Host-directed therapeutics for tuberculosis: can we harness the host? Microbiol Mol Biol Rev 2013,77(4),608-627","journal-title":"Microbiol Mol Biol Rev"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1021\/mp4006563","volume":"11","author":"Gupta A.","year":"2014","unstructured":"Gupta A.; Pant G.; Mitra K.; Madan J.; Chourasia M.K.; Misra A.; Inhalable particles containing rapamycin for induction of autophagy in macrophages infected with Mycobacterium tuberculosis. Mol Pharm 2014,11(4),1201-1207","journal-title":"Mol Pharm"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"15010","DOI":"10.1038\/s41598-017-15290-z","volume":"7","author":"Khan A.","year":"2017","unstructured":"Khan A.; Mann L.; Papanna R.; Lyu M.A.; Singh C.R.; Olson S.; Eissa N.T.; Cirillo J.; Das G.; Hunter R.L.; Jagannath C.; Mesenchymal stem cells internalize Mycobacterium tuberculosis through scavenger receptors and restrict bacterial growth through autophagy. Sci Rep 2017,7(1),15010","journal-title":"Sci Rep"},{"key":"ref=71","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3009885","volume":"6","author":"Singhal A.","year":"2014","unstructured":"Singhal A.; Jie L.; Kumar P.; Hong G.S.; Leow M.K.; Paleja B.; Tsenova L.; Kurepina N.; Chen J.; Zolezzi F.; Kreiswirth B.; Poidinger M.; Chee C.; Kaplan G.; Wang Y.T.; De Libero G.; Metformin as adjunct antituberculosis therapy. Sci Transl Med 2014,6(263)","journal-title":"Sci Transl Med"},{"key":"ref=72","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024363","volume":"9","author":"Padmapriyadarsini C.","year":"2019","unstructured":"Padmapriyadarsini C.; Bhavani P.K.; Natrajan M.; Ponnuraja C.; Kumar H.; Gomathy S.N.; Guleria R.; Jawahar S.M.; Singh M.; Balganesh T.; Swaminathan S.; Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): Study protocol for a randomised clinical trial. BMJ Open 2019,9(3)","journal-title":"BMJ Open"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"7115","DOI":"10.4049\/jimmunol.181.10.7115","volume":"181","author":"Krutzik S.R.","year":"2008","unstructured":"Krutzik S.R.; Hewison M.; Liu P.T.; Robles J.A.; Stenger S.; Adams J.S.; Modlin R.L.; IL-15 links TLR2\/1-induced macrophage differentiation to the vitamin D-dependent antimicrobial pathway. J Immunol 2008,181(10),7115-7120","journal-title":"J Immunol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.clim.2009.06.009","volume":"133","author":"Anand S.P.","year":"2009","unstructured":"Anand S.P.; Selvaraj P.; Effect of 1, 25 dihydroxyvitamin D(3) on matrix metalloproteinases MMP-7, MMP-9 and the inhibitor TIMP-1 in pulmonary tuberculosis. Clin Immunol 2009,133(1),126-131","journal-title":"Clin Immunol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1126\/science.1123933","volume":"311","author":"Liu P.T.","year":"2006","unstructured":"Liu P.T.; Stenger S.; Li H.; Wenzel L.; Tan B.H.; Krutzik S.R.; Ochoa M.T.; Schauber J.; Wu K.; Meinken C.; Kamen D.L.; Wagner M.; Bals R.; Steinmeyer A.; Z\u00fcgel U.; Gallo R.L.; Eisenberg D.; Hewison M.; Hollis B.W.; Adams J.S.; Bloom B.R.; Modlin R.L.; Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006,311(5768),1770-1773","journal-title":"Science"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1128\/mBio.02087-17","volume":"8","author":"Robinson R.T.","year":"2017","unstructured":"Robinson R.T.; T Cell Production of GM-CSF Protects the Host during Experimental Tuberculosis. MBio 2017,8(6),8","journal-title":"MBio"},{"key":"ref=77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083843","volume":"8","author":"Chen C.","year":"2013","unstructured":"Chen C.; Liu Q.; Zhu L.; Yang H.; Lu W.; Vitamin D receptor gene polymorphisms on the risk of tuberculosis, a meta-analysis of 29 case-control studies. PLoS One 2013,8(12)","journal-title":"PLoS One"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jcte.2014.08.002","volume":"1","author":"Kearns M.D.","year":"2014","unstructured":"Kearns M.D.; Tangpricha V.; The role of vitamin D in tuberculosis. J Clin Transl Endocrinol 2014,1(4),167-169","journal-title":"J Clin Transl Endocrinol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.tube.2013.02.012","volume":"93","author":"Verma R.K.","year":"2013","unstructured":"Verma R.K.; Agrawal A.K.; Singh A.K.; Mohan M.; Gupta A.; Gupta P.; Gupta U.D.; Misra A.; Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill Mycobacterium tuberculosis. Tuberculosis (Edinb) 2013,93(4),412-417","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1021\/mp300269g","volume":"9","author":"Verma R.K.","year":"2012","unstructured":"Verma R.K.; Singh A.K.; Mohan M.; Agrawal A.K.; Verma P.R.; Gupta A.; Misra A.; Inhalable microparticles containing nitric oxide donors: saying NO to intracellular Mycobacterium tuberculosis. Mol Pharm 2012,9(11),3183-3189","journal-title":"Mol Pharm"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/S0264-410X(00)00519-3","volume":"19","author":"Agger E.M.","year":"2001","unstructured":"Agger E.M.; Andersen P.; Tuberculosis subunit vaccine development: on the role of interferon-gamma. Vaccine 2001,19(17-19),2298-2302","journal-title":"Vaccine"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1128\/IAI.03004-14","volume":"83","author":"Rafi W.","year":"2015","unstructured":"Rafi W.; Bhatt K.; Gause W.C.; Salgame P.; Neither primary nor memory immunity to Mycobacterium tuberculosis infection is compromised in mice with chronic enteric helminth infection. Infect Immun 2015,83(3),1217-1223","journal-title":"Infect Immun"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1084\/jem.20062105","volume":"204","author":"Scott-Browne J.P.","year":"2007","unstructured":"Scott-Browne J.P.; Shafiani S.; Tucker-Heard G.; Ishida-Tsubota K.; Fontenot J.D.; Rudensky A.Y.; Bevan M.J.; Urdahl K.B.; Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. J Exp Med 2007,204(9),2159-2169","journal-title":"J Exp Med"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/1521-4141(200206)32:6<1605:AID-IMMU1605>3.0.CO;2-6","volume":"32","author":"Lienhardt C.","year":"2002","unstructured":"Lienhardt C.; Azzurri A.; Amedei A.; Fielding K.; Sillah J.; Sow O.Y.; Bah B.; Benagiano M.; Diallo A.; Manetti R.; Manneh K.; Gustafson P.; Bennett S.; D\u2019Elios M.M.; McAdam K.; Del Prete G.; Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. Eur J Immunol 2002,32(6),1605-1613","journal-title":"Eur J Immunol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1128\/IAI.72.3.1358-1363.2004","volume":"72","author":"Allen S.S.","year":"2004","unstructured":"Allen S.S.; Cassone L.; Lasco T.M.; McMurray D.N.; Effect of neutralizing transforming growth factor beta1 on the immune response against Mycobacterium tuberculosis in guinea pigs. Infect Immun 2004,72(3),1358-1363","journal-title":"Infect Immun"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"16508","DOI":"10.1074\/jbc.M114.558098","volume":"289","author":"Bhattacharya D.","year":"2014","unstructured":"Bhattacharya D.; Dwivedi V.P.; Maiga M.; Maiga M.; Van Kaer L.; Bishai W.R.; Das G.; Small molecule-directed immunotherapy against recurrent infection by Mycobacterium tuberculosis. J Biol Chem 2014,289(23),16508-16515","journal-title":"J Biol Chem"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"33404","DOI":"10.1074\/jbc.M114.600452","volume":"289","author":"Bhattacharya D.","year":"2014","unstructured":"Bhattacharya D.; Dwivedi V.P.; Kumar S.; Reddy M.C.; Van Kaer L.; Moodley P.; Das G.; Simultaneous inhibition of T helper 2 and T regulatory cell differentiation by small molecules enhances Bacillus Calmette-Guerin vaccine efficacy against tuberculosis. J Biol Chem 2014,289(48),33404-33411","journal-title":"J Biol Chem"},{"key":"ref=88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008356","volume":"16","author":"Ahmad S.","year":"2020","unstructured":"Ahmad S.; Bhattacharya D.; Gupta N.; Rawat V.; Tousif S.; Van Kaer L.; Das G.; Clofazimine enhances the efficacy of BCG revaccination via stem cell-like memory T cells. PLoS Pathog 2020,16(5)","journal-title":"PLoS Pathog"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3389\/fcimb.2017.00149","volume":"7","author":"Dwivedi V.P.","year":"2017","unstructured":"Dwivedi V.P.; Bhattacharya D.; Yadav V.; Singh D.K.; Kumar S.; Singh M.; Ojha D.; Ranganathan A.; Van Kaer L.; Chattopadhyay D.; Das G.; The Phytochemical Bergenin Enhances T Helper 1 Responses and Anti-Mycobacterial Immunity by Activating the MAP Kinase Pathway in Macrophages. Front Cell Infect Microbiol 2017,7,149","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2174\/187152809787582543","volume":"8","author":"Mootoo A.","year":"2009","unstructured":"Mootoo A.; Stylianou E.; Arias M.A.; Reljic R.; TNF-alpha in tuberculosis: a cytokine with a split personality. Inflamm Allergy Drug Targets 2009,8(1),53-62","journal-title":"Inflamm Allergy Drug Targets"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1093\/infdis\/jit476","volume":"208","author":"Eisen D.P.","year":"2013","unstructured":"Eisen D.P.; McBryde E.S.; Walduck A.; Low-dose aspirin and ibuprofen\u2019s sterilizing effects on Mycobacterium tuberculosis suggest safe new adjuvant therapies for tuberculosis. J Infect Dis 2013,208(11),1925-1927","journal-title":"J Infect Dis"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/femsre\/fuy043","volume":"43","author":"Bengoechea J.A.","year":"2019","unstructured":"Bengoechea J.A.; Sa Pessoa J.; Klebsiella pneumoniae infection biology: living to counteract host defences. FEMS Microbiol Rev 2019,43(2),123-144","journal-title":"FEMS Microbiol Rev"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/mBio.02802-19","volume":"10","author":"Dumigan A.","year":"2019","unstructured":"Dumigan A.; Fitzgerald M.; Santos J.S.G.; Hamid U.; O\u2019Kane C.M.; McAuley D.F.; Bengoechea J.A.; A Porcine Ex Vivo Lung Perfusion Model To Investigate Bacterial Pathogenesis. MBio 2019,10(6),10","journal-title":"MBio"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1128\/mBio.01932-17","volume":"9","author":"Chiang C.Y.","year":"2018","unstructured":"Chiang C.Y.; Uzoma I.; Moore R.T.; Gilbert M.; Duplantier A.J.; Panchal R.G.; Mitigating the Impact of Antibacterial Drug Resistance through Host-Directed Therapies: Current Progress, Outlook, and Challenges. MBio 2018,9(1),9","journal-title":"MBio"},{"key":"ref=95","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3578702","volume":"2017","author":"Zhang G.","year":"2017","unstructured":"Zhang G.; Lin X.; Zhang S.; Xiu H.; Pan C.; Cui W.; A Protective Role of Glibenclamide in Inflammation-Associated Injury. Mediators Inflamm 2017,2017","journal-title":"Mediators Inflamm"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1182\/blood.V90.8.2911","volume":"90","author":"Hamon Y.","year":"1997","unstructured":"Hamon Y.; Luciani M.F.; Becq F.; Verrier B.; Rubartelli A.; Chimini G.; Interleukin-1beta secretion is impaired by inhibitors of the Atp binding cassette transporter, ABC1. Blood 1997,90(8),2911-2915","journal-title":"Blood"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1083\/jcb.200903124","volume":"187","author":"Lamkanfi M.","year":"2009","unstructured":"Lamkanfi M.; Mueller J.L.; Vitari A.C.; Misaghi S.; Fedorova A.; Deshayes K.; Lee W.P.; Hoffman H.M.; Dixit V.M.; Glyburide inhibits the Cryopyrin\/Nalp3 inflammasome. J Cell Biol 2009,187(1),61-70","journal-title":"J Cell Biol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/cid\/ciq192","volume":"52","author":"Koh G.C.","year":"2011","unstructured":"Koh G.C.; Maude R.R.; Schreiber M.F.; Limmathurotsakul D.; Wiersinga W.J.; Wuthiekanun V.; Lee S.J.; Mahavanakul W.; Chaowagul W.; Chierakul W.; White N.J.; van der Poll T.; Day N.P.; Dougan G.; Peacock S.J.; Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis. Clin Infect Dis 2011,52(6),717-725","journal-title":"Clin Infect Dis"},{"key":"ref=99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002500","volume":"7","author":"Koh G.C.","year":"2013","unstructured":"Koh G.C.; Weehuizen T.A.; Breitbach K.; Krause K.; de Jong H.K.; Kager L.M.; Hoogendijk A.J.; Bast A.; Peacock S.J.; van der Poll T.; Steinmetz I.; Wiersinga W.J.; Glyburide reduces bacterial dissemination in a mouse model of melioidosis. PLoS Negl Trop Dis 2013,7(10)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nm.3911","volume":"21","author":"Dalli J.","year":"2015","unstructured":"Dalli J.; Chiang N.; Serhan C.N.; Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections. Nat Med 2015,21(9),1071-1075","journal-title":"Nat Med"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1056\/NEJMcibr1511280","volume":"373","author":"Lee C.R.","year":"2015","unstructured":"Lee C.R.; Zeldin D.C.; Resolvin infectious inflammation by targeting the host response. N Engl J Med 2015,373(22),2183-2185","journal-title":"N Engl J Med"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nature06345","volume":"450","author":"Kuijl C.","year":"2007","unstructured":"Kuijl C.; Savage N.D.; Marsman M.; Tuin A.W.; Janssen L.; Egan D.A.; Ketema M.; van den Nieuwendijk R.; van den Eeden S.J.; Geluk A.; Poot A.; van der Marel G.; Beijersbergen R.L.; Overkleeft H.; Ottenhoff T.H.; Neefjes J.; Intracellular bacterial growth is controlled by a kinase network around PKB\/AKT1. Nature 2007,450(7170),725-730","journal-title":"Nature"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/cmi.12110","volume":"15","author":"Frank C.G.","year":"2013","unstructured":"Frank C.G.; Reguerio V.; Rother M.; Moranta D.; Maeurer A.P.; Garmendia J.; Meyer T.F.; Bengoechea J.A.; Klebsiella pneumoniae targets an EGF receptor-dependent pathway to subvert inflammation. Cell Microbiol 2013,15(7),1212-1233","journal-title":"Cell Microbiol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1158\/0008-5472.CAN-03-3852","volume":"64","author":"Widschwendter M.","year":"2004","unstructured":"Widschwendter M.; Siegmund K.D.; M\u00fcller H.M.; Fiegl H.; Marth C.; M\u00fcller-Holzner E.; Jones P.A.; Laird P.W.; Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004,64(11),3807-3813","journal-title":"Cancer Res"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/1423-0127-16-110","volume":"16","author":"Chiu H.C.","year":"2009","unstructured":"Chiu H.C.; Soni S.; Kulp S.K.; Curry H.; Wang D.; Gunn J.S.; Schlesinger L.S.; Chen C.S.; Eradication of intracellular Francisella tularensis in THP-1 human macrophages with a novel autophagy inducing agent. J Biomed Sci 2009,16,110","journal-title":"J Biomed Sci"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"7375","DOI":"10.1128\/AAC.03778-14","volume":"58","author":"Lo J.H.","year":"2014","unstructured":"Lo J.H.; Kulp S.K.; Chen C.S.; Chiu H.C.; Sensitization of intracellular Salmonella enterica serovar Typhimurium to aminoglycosides in vitro and in vivo by a host-targeted antimicrobial agent. Antimicrob Agents Chemother 2014,58(12),7375-7382","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"5236","DOI":"10.1128\/AAC.00555-09","volume":"53","author":"Chiu H.C.","year":"2009","unstructured":"Chiu H.C.; Kulp S.K.; Soni S.; Wang D.; Gunn J.S.; Schlesinger L.S.; Chen C.S.; Eradication of intracellular Salmonella enterica serovar Typhimurium with a small-molecule, host cell-directed agent. Antimicrob Agents Chemother 2009,53(12),5236-5244","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=108","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004912","volume":"5","author":"Das B.","year":"2013","unstructured":"Das B.; Kashino S.S.; Pulu I.; Kalita D.; Swami V.; Yeger H.; Felsher D.W.; Campos-Neto A.; CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. Sci Transl Med 2013,5(170)","journal-title":"Sci Transl Med"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S2213-2600(13)70234-0","volume":"2","author":"Skrahin A.","year":"2014","unstructured":"Skrahin A.; Ahmed R.K.; Ferrara G.; Rane L.; Poiret T.; Isaikina Y.; Skrahina A.; Zumla A.; Maeurer M.J.; Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med 2014,2(2),108-122","journal-title":"Lancet Respir Med"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1056\/NEJMc1713777","volume":"379","author":"Das S.","year":"2018","unstructured":"Das S.; Saha B.; Hati A.K.; Roy S.; Evidence of Artemisinin-Resistant Plasmodium falciparum Malaria in Eastern India. N Engl J Med 2018,379(20),1962-1964","journal-title":"N Engl J Med"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/1745-6215-12-176","volume":"12","author":"Hawkes M.","year":"2011","unstructured":"Hawkes M.; Opoka R.O.; Namasopo S.; Miller C.; Thorpe K.E.; Lavery J.V.; Conroy A.L.; Liles W.C.; John C.C.; Kain K.C.; Inhaled nitric oxide for the adjunctive therapy of severe malaria: protocol for a randomized controlled trial. Trials 2011,12,176","journal-title":"Trials"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1084\/jem.184.2.557","volume":"184","author":"Anstey N.M.","year":"1996","unstructured":"Anstey N.M.; Weinberg J.B.; Hassanali M.Y.; Mwaikambo E.D.; Manyenga D.; Misukonis M.A.; Arnelle D.R.; Hollis D.; McDonald M.I.; Granger D.L.; Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production\/nitric oxide synthase type 2 expression. J Exp Med 1996,184(2),557-567","journal-title":"J Exp Med"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1084\/jem.20070819","volume":"204","author":"Yeo T.W.","year":"2007","unstructured":"Yeo T.W.; Lampah D.A.; Gitawati R.; Tjitra E.; Kenangalem E.; McNeil Y.R.; Darcy C.J.; Granger D.L.; Weinberg J.B.; Lopansri B.K.; Price R.N.; Duffull S.B.; Celermajer D.S.; Anstey N.M.; Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. J Exp Med 2007,204(11),2693-2704","journal-title":"J Exp Med"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1182\/blood-2014-04-567149","volume":"125","author":"Smith C.M.","year":"2015","unstructured":"Smith C.M.; Jerkovic A.; Puy H.; Winship I.; Deybach J.C.; Gouya L.; van Dooren G.; Goodman C.D.; Sturm A.; Manceau H.; McFadden G.I.; David P.; Mercereau-Puijalon O.; Burgio G.; McMorran B.J.; Foote S.J.; Red cells from ferrochelatase-deficient erythropoietic protoporphyria patients are resistant to growth of malarial parasites. Blood 2015,125(3),534-541","journal-title":"Blood"},{"key":"ref=115","first-page":"91","volume":"86","author":"Kwiatkowski D.","year":"1993","unstructured":"Kwiatkowski D.; Molyneux M.E.; Stephens S.; Curtis N.; Klein N.; Pointaire P.; Smit M.; Allan R.; Brewster D.R.; Grau G.E.; Anti-TNF therapy inhibits fever in cerebral malaria. Q J Med 1993,86(2),91-98","journal-title":"Q J Med"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1046\/j.1365-2567.1997.00290.x","volume":"91","author":"Kossodo S.","year":"1997","unstructured":"Kossodo S.; Monso C.; Juillard P.; Velu T.; Goldman M.; Grau G.E.; Interleukin-10 modulates susceptibility in experimental cerebral malaria. Immunology 1997,91(4),536-540","journal-title":"Immunology"},{"key":"ref=117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029442","volume":"7","author":"Vathsala P.G.","year":"2012","unstructured":"Vathsala P.G.; Dende C.; Nagaraj V.A.; Bhattacharya D.; Das G.; Rangarajan P.N.; Padmanaban G.; Curcumin-arteether combination therapy of Plasmodium berghei-infected mice prevents recrudescence through immunomodulation. PLoS One 2012,7(1)","journal-title":"PLoS One"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3389\/fimmu.2017.01329","volume":"8","author":"Boyle M.J.","year":"2017","unstructured":"Boyle M.J.; Jagannathan P.; Bowen K.; McIntyre T.I.; Vance H.M.; Farrington L.A.; Schwartz A.; Nankya F.; Naluwu K.; Wamala S.; Sikyomu E.; Rek J.; Greenhouse B.; Arinaitwe E.; Dorsey G.; Kamya M.R.; Feeney M.E.; The Development of Plasmodium falciparum-Specific IL10 CD4 T Cells and Protection from Malaria in Children in an Area of High Malaria Transmission. Front Immunol 2017,8,1329","journal-title":"Front Immunol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.chom.2013.06.003","volume":"14","author":"Matheoud D.","year":"2013","unstructured":"Matheoud D.; Moradin N.; Bellemare-Pelletier A.; Shio M.T.; Hong W.J.; Olivier M.; Gagnon E.; Desjardins M.; Descoteaux A.; Leishmania evades host immunity by inhibiting antigen cross-presentation through direct cleavage of the SNARE VAMP8. Cell Host Microbe 2013,14(1),15-25","journal-title":"Cell Host Microbe"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1086\/314520","volume":"178","author":"Gomes N.A.","year":"1998","unstructured":"Gomes N.A.; Barreto-de-Souza V.; Wilson M.E.; DosReis G.A.; Unresponsive CD4+ T lymphocytes from Leishmania chagasi-infected mice increase cytokine production and mediate parasite killing after blockade of B7-1\/CTLA-4 molecular pathway. J Infect Dis 1998,178(6),1847-1851","journal-title":"J Infect Dis"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/eji.200324021","volume":"34","author":"Zubairi S.","year":"2004","unstructured":"Zubairi S.; Sanos S.L.; Hill S.; Kaye P.M.; Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani. Eur J Immunol 2004,34(5),1433-1440","journal-title":"Eur J Immunol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/infdis\/jit550","volume":"209","author":"Parihar S.P.","year":"2014","unstructured":"Parihar S.P.; Guler R.; Khutlang R.; Lang D.M.; Hurdayal R.; Mhlanga M.M.; Suzuki H.; Marais A.D.; Brombacher F.; Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J Infect Dis 2014,209(5),754-763","journal-title":"J Infect Dis"},{"key":"ref=123","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075490","volume":"8","author":"Parihar S.P.","year":"2013","unstructured":"Parihar S.P.; Guler R.; Lang D.M.; Suzuki H.; Marais A.D.; Brombacher F.; Simvastatin enhances protection against Listeria monocytogenes infection in mice by counteracting Listeria-induced phagosomal escape. PLoS One 2013,8(9)","journal-title":"PLoS One"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.pt.2006.12.003","volume":"23","author":"Pucadyil T.J.","year":"2007","unstructured":"Pucadyil T.J.; Chattopadhyay A.; Cholesterol: a potential therapeutic target in Leishmania infection? Trends Parasitol 2007,23(2),49-53","journal-title":"Trends Parasitol"}],"container-title":["Combinatorial Chemistry &amp; High Throughput Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/184210","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/184210\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/184210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T13:22:38Z","timestamp":1638624158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/184210\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":124,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,13]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1386207323999200728115857","relation":{},"ISSN":["1386-2073"],"issn-type":[{"value":"1386-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,13]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-01-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}